Global Psoriatic Arthritis Treatment Market to Reach US$ 21.8 Billion by 2032, Impelled by Rising Prevalence of Autoimmune Illnesses

September 19, 2022 | Healthcare

According to the latest report by IMARC Group, titled "Psoriatic Arthritis Treatment Market Report by Drug Type (NSAIDs (Nonsteroidal Anti-Inflammatory drugs), DMARDs (Disease-Modifying Anti-Rheumatic Drugs), Biologics, and Others), Type (Prescription, OTC), Route of Administration (Injectable, Oral, Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032," the global psoriatic arthritis treatment market reached a value of US$ 9.7 Billion in 2023. Psoriatic arthritis is a form of a disease that affects any part of the body, causing stiffness, joint pain and swelling. It is generally prevalent in patients suffering from plaque psoriasis that develops patches of red, flaky skin with silvery and white scales. Its treatment is commonly available in the form of oral medications as well as biological therapies that aid in controlling symptoms and preventing joint damage. Due to the increasing awareness among the masses regarding the adverse effects of the chronic degenerative condition, there has been a considerable rise in the adoption of psoriatic arthritis treatment.

Global Psoriatic Arthritis Treatment Market Trends:

The global market is primarily driven by the growing prevalence of autoimmune illnesses among the masses. This is supported by the increasing occurrence of infections and skin injuries, coupled with the rising population leading sedentary lifestyles resulting in obesity and stress. Along with this, multiple initiatives undertaken by private and public organizations, such as conducting campaigning and medical programs, in order to create awareness among individuals are catalyzing the demand for psoriatic arthritis treatment across the globe. Moreover, the growing investments by leading players for conducting extensive research and development (R&D) activities to introduce improved treatment options are creating a positive market outlook. Additionally, continual technological advancements and the emergence of biosimilars and biological therapies are impacting the market growth favorably. Other factors, including the increasing geriatric population, growing patient pool, continual improvements in the healthcare infrastructure and the development of medical facilities across rural and geographical extended locations, are also positively influencing the market. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 21.8 Billion by 2032, exhibiting a CAGR of 9.2% during 2024-2032.

Market Summary:

  • On the basis of drug type, the market has been segmented into NSAIDs (nonsteroidal anti-inflammatory drugs), DMARDs (disease-modifying anti-rheumatic drugs), biologics and others.
  • Based on the type, the market has been segregated into prescription and OTC.
  • On the basis of the route of administration, the market has been categorized into injectable, oral and topical.
  • Based on the distribution channel, the market has been classified into hospital, retail and online pharmacies.
  • On the basis of the region, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil, Mexico and others) and the Middle East and Africa.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of the key players are AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals LLC, AstraZeneca plc, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Johnson & Johnson Service ltd., Novartis AG, Pfizer Inc., Samsung Biologics and UCB S.A.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Drug Type, Type, Route of Administration, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals LLC, AstraZeneca plc, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Johnson & Johnson Service ltd., Novartis AG, Pfizer Inc., Samsung Biologics and UCB S.A.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Psoriatic Arthritis Treatment Market to Reach US$ 21.8 Billion by 2032, Impelled by Rising Prevalence of Autoimmune Illnesses
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More